Regenerative Medicine (RM) has the promise to revolutionize the treatment of many debilitating diseases for which the current therapies are inadequate. To realize the full potential of RM, a pragmatic approach needs to be taken by all stakeholders keeping in mind the lessons learnt from recombinant protein manufacturing, gene therapy trials, etc., to develop novel service delivery models for economic viability and regulatory processes in the absence of long-term data. In this chapter, we focus on the three main drivers of RM field and discuss the potential pitfalls and possible ways to mitigate them in order to move the field closer to clinical implementation.